http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2342140-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7257cb73f07e30a668fd426fe1914ed
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
filingDate 2003-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2008-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0d720b1cbf3c867bc00eeb7dbd93a075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_237e9f69ea2f481a21c88679a486ddf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_825e8f108eab9f789029403ea548df25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c3d13eefe514ce6728d95e641040fb2
publicationDate 2008-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2342140-C2
titleOfInvention Indolinone and chemotherapeutic agent combined administration in conditions, caused by cell proliferation
abstract FIELD: medicine; oncology. n SUBSTANCE: versions of method include combined administration of 5-(5-fluoro-2-oxo-1,2-dihydroindole-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrol-3-carboxylic acid (2-diethylaminoethyl)amide and docetaxel in low doses that are ineffective in single-drug therapy. n EFFECT: synergistic anti-tumour effect, lowered doses of each drug. n 2 cl, 8 dwg, 8 tbl,24 ex
priorityDate 2002-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3086686
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID152757772
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492617
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421146235
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419518569
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID321710
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425795698

Total number of triples: 38.